Yannis Valtis

15PUBLICATIONS
93CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 06, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.

Yannis K Valtis, Chenyu Lin, David Nemirovsky

|Sep 27, 2025
Venetoclax in Combination With Pediatric-Inspired Chemotherapy in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial.

Yannis K Valtis, David Nemirovsky, Andriy Derkach

|Apr 21, 2025
T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.

Kai Rejeski, Jaime Sanz, Teng Fei

|Apr 08, 2025
Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Meira Yisraeli Salman, Alexander R Terry, Andriy Derkach

|Jan 30, 2025
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma.

Jae H Park, M Lia Palomba, Karlo Perica

|Nov 19, 2024
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.

Monica S Nair, Sara K Silbert, Kai Rejeski

Pageof 3

Frequent Collaborators

3 joint publications

Gilles Salles

3 joint publications

Nirali N Shah

3 joint publications

Marlise R Luskin

2 joint publications

Miguel-Angel Perales